Cusabio Polyclonal Antibodies
Phospho-MAP2K2 (Thr394) Antibody | CSB-PA062510
- SKU:
- CSB-PA062510
- Availability:
- 3 to 7 Working Days
- Size:
- 100ul
Description
Phospho-MAP2K2 (Thr394) Antibody | CSB-PA062510 | Cusabio
Phospho-MAP2K2 (Thr394) Antibody is Available at Gentaur Genprice with the fastest delivery.
Online Order Payment is possible or send quotation to info@gentaur.com.
Product Type: Polyclonal Antibody
Target Names: MAP2K2
Aliases: ERK activator kinase 2; MAP kinase kinase 2; MAP2K2; MAPK/ERK kinase 2; MAPKK 2
Background: Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
Crews C M, et al. (1992) Science. 258:478-480.
Alessi D R, et al. (1994) EMBO J. 13:1610-1619.
Rosen L B, et al. (1994) Neuron. 12:1207-1221.
Cowley S, et al. (1994) Cell. 77:841-852.
Isotype: IgG
Conjugate: Non-conjugated
Clonality: Polyclonal
Uniport ID: P36507
Host Species: Rabbit
Species Reactivity: Human, Mouse, Rat
Immunogen: Peptide sequence around phosphorylation site of threonine 394 (P-G-T (p) -P-T) derived from Human MEK-2.
Immunogen Species: Human
Applications: ELISA, WB, IHC, IF
Tested Applications: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:100, IF:1:100-1:200
Purification Method: Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
Dilution Ratio1: ELISA:1:2000-1:10000
Dilution Ratio2: WB:1:500-1:1000
Dilution Ratio3: IHC:1:50-1:100
Dilution Ratio4: IF:1:100-1:200
Dilution Ratio5:
Dilution Ratio6:
Buffer: Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form: liquid
Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Initial Research Areas: Signal Transduction
Research Areas: Cancer;Signal transduction